Business Wire – Wed Sep 24, 6:00AM CDT
Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.
Three Growth Platforms
Clinical-Trial AI Platform – Primary Near-Term Driver
Predictmedix is developing an adaptive-AI engine designed to simulate, optimize, and predict outcomes across multi-site clinical trials—addressing a global clinical trials market projected to reach USD $123.5 billion by 2030, growing at a CAGR of ~6.5 % from 2024 to 2030 1 .
The SaaS-based platform is intended to provide trial simulation, cross-trial learning, cost/outcome modeling, and full regulatory traceability.
SmartHealth AI Stations – Global Commercialization
The Company’s contactless, screening systems have demonstrated approximately 95% accuracy in detecting impairment, infectious disease, and multiple vital signs, supported by independent, multi-center clinical validation. Predictmedix is assessing regulatory requirements in multiple jurisdictions, including Southeast Asia, and plans to initiate formal medical-device certification processes as a next step toward global deployment for enterprise health & safety, hospital triage, and government health programs.
Consumer Vital-Scanning Mobile Application – Direct-to-Consumer Entry
A planned mobile application will leverage Predictmedix’s patented imaging technology to deliver vital-sign monitoring through a smartphone, extending the Company’s platform into the growing digital-health and telehealth markets.
Strategic Rationale
- Recurring revenue potential: SaaS subscriptions for the Clinical-Trial AI platform; Screening-as-a-Service for enterprises and hospitals; consumer subscriptions for the mobile app.
- Defensible IP: Proprietary adaptive-simulation engine and patented multispectral imaging algorithms.
- Large addressable markets: The global AI in healthcare market was estimated at USD $26.6 billion in 2024 and is projected to reach approximately USD $187.7 billion by 2030, growing at a ~38.6 % CAGR from 2025-2030. 2
“Our validated SmartHealth technology provides the data, AI engine, and market credibility to scale across enterprise, clinical-research, and consumer segments,” said Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix. “This multi-vertical approach is designed to diversify revenue and support sustainable long-term growth for our shareholders.”
Details of the company’s recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at:
About Predictmedix AI Inc.
Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter , Instagram or LinkedIn .
Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
View source version on businesswire.com:
link